All In Biotech

Drug Trial Radar · NCT06736262

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Open-Label Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Chronic Urticaria

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

67

Actual

Start

Nov 26, 2024

Primary completion

Jul 21, 2026

Study completion Jul 21, 2026

Sponsor

Lead sponsor
Jasper Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.

Conditions

  • Urticaria Chronic

Interventions

  • BriquilimabDrug

    No additional details needed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of briquilimabTime frame: From signing the informed consent form through study completion (an average of one year)

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigative Site 118

    Birmingham, Alabama

  • Investigative Site 108

    Little Rock, Arkansas

  • Investigative Site 105

    San Diego, California

  • Investigative Site 116

    Tampa, Florida

  • Investigative Site 109

    Boise, Idaho

  • Investigative Site 124

    Normal, Illinois

  • Investigative Site 110

    Indianapolis, Indiana

  • Investigative Site 123

    Lafayette, Louisiana

  • Investigative Site 101

    Baltimore, Maryland

  • Investigative Site 121

    White Marsh, Maryland

  • Investigative Site 103

    Cincinnati, Ohio

  • Investigative Site 111

    Murray, Utah

  • Investigative Site 115

    Seattle, Washington

  • Investigative Site 201

    Berlin, Germany

  • Investigative Site 210

    München, Bavaria, Germany

  • Investigative Site 202

    Marburg, Hesse, Germany

  • Investigative Site 204

    Münster, North Rhine-Westphalia, Germany

  • Investigative Site 209

    Dresden, Saxony, Germany

  • Investigative Site 206

    Lübeck, Schleswig-Holstein, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.